Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

HILL, BRADLEY

NPI: 1114956687 · ANTIOCH, TN 37013 · Pain Medicine (Anesthesiology) Physician · NPI assigned 06/30/2006

$135K
Total Medicaid Paid
4,682
Total Claims
3,915
Beneficiaries
18
Codes Billed
2019-11
First Month
2020-12
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2019 219 $7K
2020 4,463 $128K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 1,054 946 $36K
64635 208 170 $28K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 392 349 $24K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 457 391 $12K
62323 126 116 $11K
64636 208 169 $10K
64493 144 107 $3K
20610 143 113 $3K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 256 229 $3K
64494 129 93 $2K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 53 44 $1K
99406 179 169 $1K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 27 13 $192.68
81025 46 41 $144.57
J1100 Injection, dexamethasone sodium phosphate, 1 mg 42 39 $16.79
G8918 Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis 518 390 $0.00
G9500 Radiation exposure indices documented in final report for procedure using fluoroscopy 182 145 $0.00
G8907 Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer or hospital admission upon discharge from the facility 518 391 $0.00